Table 1 Clinical characteristics of MM... | American Society of Hematology

Table 1

Clinical characteristics of MM patients

Patient no.	Disease status at time of sampling	Gender	Response to bortezomib	Bz (5 nM)	Specific viability ex vivo (%) FK866 (3 nM)	Combination (CI)
1	Diagnosis	M	Sensitive	66	72.4	41 (0.8)
2	Relapse	F	Sensitive	54.4	68.8	35.6 (0.9)
3	Relapse	M	Resistant	74.2	74.1	54.8 (0.8)
4	Refractory	F	Resistant	79.5	72.4	55.2 (0.7)
5	Refractory	F	Resistant	74.4	82.5	54.4 (0.5)
6	Relapse	F	Sensitive	26	40	0.5 (0.3)
7	Diagnosis	M	Sensitive	63.9	84.5	46.48 (0.6)
8	Relapse	M	Resistant	89.6	88	73.4 (0.1)
9	Relapse	M	Sensitive	57	44.5	13 (0.7)
10	Refractory	F	Resistant	93	89.1	63.4 (0.5)
11	Refractory	F	Resistant	92.4	92.4	69.2 (0.5)

Patient no.	Disease status at time of sampling	Gender	Response to bortezomib	Bz (5 nM)	Specific viability ex vivo (%) FK866 (3 nM)	Combination (CI)
1	Diagnosis	M	Sensitive	66	72.4	41 (0.8)
2	Relapse	F	Sensitive	54.4	68.8	35.6 (0.9)
3	Relapse	M	Resistant	74.2	74.1	54.8 (0.8)
4	Refractory	F	Resistant	79.5	72.4	55.2 (0.7)
5	Refractory	F	Resistant	74.4	82.5	54.4 (0.5)
6	Relapse	F	Sensitive	26	40	0.5 (0.3)
7	Diagnosis	M	Sensitive	63.9	84.5	46.48 (0.6)
8	Relapse	M	Resistant	89.6	88	73.4 (0.1)
9	Relapse	M	Sensitive	57	44.5	13 (0.7)
10	Refractory	F	Resistant	93	89.1	63.4 (0.5)
11	Refractory	F	Resistant	92.4	92.4	69.2 (0.5)

Bz, bortezomib.